ArticleJournal of advanced pharmaceutical technology & research
Hesperidin increases the
Article in Journal of advanced pharmaceutical technology & research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pentagamavunon-1 (PGV-1) is a potential anticancer candidate due to its specific targeting of cancer cells with minimal toxicity to normal cells. This study examined the potency of hesperidin (HSD) in improving the anticancer effects of PGV-1 for triple-negative breast cancer (TNBC). The 4T1 and NIH-3T3 cell lines were used as the model of TNBC and normal fibroblast, respectively. The cytotoxicity was quantified using MTT and clonogenic assays, whereas the cell cycle and apoptosis were measured by flow cytometry. Cell migration was assessed by scratch-wound healing assay. Senescence was measured using the SA-β-gal assay, and the secretion of matrix metalloproteinase (MMP)-2 and 9 was examined using gelatin zymography. Protein expression level was analyzed through capillary Western blot. The collected data were quantified using one-way ANOVA. PGV-1 significantly reduced 4T1 cell viability, with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.